David A. Siegel Tg Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 166,100 shares of TGTX stock, worth $5.13 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
166,100Holding current value
$5.13 Million% of portfolio
0.01%Shares
18 transactions
Others Institutions Holding TGTX
# of Institutions
331Shares Held
93.1MCall Options Held
1.72MPut Options Held
1.29M-
Vanguard Group Inc Valley Forge, PA15.4MShares$476 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$352 Million0.0% of portfolio
-
State Street Corp Boston, MA6.7MShares$207 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.65MShares$113 Million6.57% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.58MShares$111 Million0.1% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.49B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...